Neutropenia
📧 Sign up to get email alerts when something new happens for Neutropenia.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2019-03-28FDA Approved: GRANIX — Supplemental Application (Cephalon, LLC)
FDA approved a supplemental application for GRANIX (tbo-filgrastim) submitted by Cephalon, LLC.
-
CLINICAL_TRIALS trial_result · 2019-03-26Clinical Trial Update: Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy [Phase 3]
Phase 3 trial update for F-627 in women with breast cancer undergoing myelotoxic chemotherapy; study completed with results posted.
-
FDA approval · 2019-03-21FDA Approved: FULPHILA — Supplemental Application (Biocon Biologics Inc.)
FDA supplemental approval for Fulphila (pegfilgrastim-jmdb) by Biocon Biologics Inc. to update/expand the approved labeling for this biosimi…
-
CLINICAL_TRIALS research · 2019-01-17Clinical Trial Update: Prevention of Febrile Neutropenia by Synbiotics in Pediatric Cancer Patients [Phase 2]
Phase 2 pediatric trial assessing whether synbiotics can prevent febrile neutropenia in children with cancer.
-
FDA approval · 2018-11-02FDA Approved: UDENYCA — Original Application (Accord BioPharma, Inc.)
FDA approved UDENYCA (pegfilgrastim-cbqv) as an original biologics license application for reducing the duration of neutropenia in patients …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2018-10-26Clinical Trial Update: Bioavailability Study of Lozanoc™ 65 mg Itraconazole Capsules in Patients Requiring Prophylaxis [Phase 2]
Phase 2 trial evaluating the bioavailability of Lozanoc 65 mg itraconazole capsules for prophylaxis in neutropenia patients has been complet…
-
CLINICAL_TRIALS trial_result · 2018-10-26Clinical Trial Update: Steady-State Comparative Bioavailability Study in Prophylaxis Patients of Lozanoc® 50 mg With Sporanox® 100 mg [Phase 4]
Phase 4 trial comparing steady-state bioavailability of Lozanoc 50 mg with Sporanox 100 mg in prophylaxis patients completed.
-
CLINICAL_TRIALS trial_result · 2018-09-27Clinical Trial Update: Safety and Efficacy of Human Myeloid Progenitor Cells (CLT-008) During Chemotherapy for Acute Myeloid Leukemia [Phase 2]
Phase 2 clinical trial update on safety and efficacy of CLT-008 human myeloid progenitor cells during chemotherapy in acute myeloid leukemia…
-
FDA approval · 2018-07-31FDA Approved: GRANIX — Supplemental Application (Cephalon, LLC)
FDA approved a supplemental application for GRANIX (TBO-FILGRASTIM) submitted by Cephalon, LLC.
-
CLINICAL_TRIALS trial_result · 2018-07-31Clinical Trial Update: A Study to Evaluate 5 μg/kg Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors Without Bone Marrow Involvement [Phase 2]
Phase 2 study evaluating 5 μg/kg Tbo-filgrastim in infants, children, and adolescents with solid tumors without bone marrow involvement has …
-
FDA approval · 2018-07-20FDA Approved: NIVESTYM — Original Application (Pfizer Laboratories Div Pfizer Inc)
The FDA approved NIVESTYM (filgrastim-aafi) from Pfizer as a biosimilar to filgrastim for reducing duration of neutropenia and infection ris…
-
CLINICAL_TRIALS trial_result · 2018-07-18Clinical Trial Update: Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia [Phase 1]
A Phase 1 clinical trial updating on prolonged versus standard infusion of cefepime hydrochloride for treating febrile neutropenia in adults…
-
FDA approval · 2018-06-18FDA Approved: NEUPOGEN — Supplemental Application (Amgen, Inc)
FDA approved a supplemental application for NEUPOGEN (filgrastim) from Amgen, Inc.
-
FDA approval · 2018-06-04FDA Approved: FULPHILA — Original Application (Biocon Biologics Inc.)
FDA approved Fulphila (pegfilgrastim-jmdb) from Biocon Biologics Inc. through an original application to help prevent neutropenia-related in…
-
CLINICAL_TRIALS trial_result · 2018-05-25Clinical Trial Update: Mouthwash With Chlorhexidine 0.12%/Ethyl Alcohol 7% Compared to Ethyl Alcohol 7% [Phase 3]
A Phase 3 trial comparing chlorhexidine gluconate mouthwash (0.12%) with 7% ethyl alcohol to ethyl alcohol alone (7%) for neutropenia has co…
-
CLINICAL_TRIALS trial_result · 2018-05-11Clinical Trial Update: Determining the Etiology of Febrile Neutropenia Using the Karius Sequencing-based Infectious Disease Diagnostic Assay
A completed clinical trial from Karius evaluated a sequencing-based infectious disease diagnostic assay to determine the etiology of febrile…
-
CLINICAL_TRIALS trial_result · 2018-04-13Clinical Trial Update: Efficacy of Granulocyte-Colony Stimulating Factor (G-CSF) [NA]
A clinical trial update reporting on the efficacy of granulocyte colony-stimulating factor (G-CSF) for neutropenia, with the trial status li…
-
CLINICAL_TRIALS research · 2018-03-27Clinical Trial Update: Community-Led Action Research in Oncology: Improving Symptom Management [NA]
This clinical trial update reports a completed community-led action research project in oncology focused on improving symptom management for…
-
CLINICAL_TRIALS trial_result · 2018-03-20Clinical Trial Update: Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy [Phase 2]
Phase 2 dose-finding trial of F-627 in women with breast cancer receiving myelotoxic chemotherapy has completed; results posted.
-
CLINICAL_TRIALS trial_result · 2018-02-23Clinical Trial Update: A Phase II, Dose-finding Study of F-627 in Patients With Breast Cancer Receiving Myelotoxic Chemotherapy. [Phase 2]
Phase II dose-finding study of F-627 in breast cancer patients receiving myelotoxic chemotherapy has completed.
-
FDA approval · 2017-12-09FDA Approved: NEULASTA — Supplemental Application (Amgen, Inc)
FDA approves a supplemental application for NEULASTA (pegfilgrastim) filed by Amgen, Inc.
-
FDA approval · 2017-06-21FDA Approved: GRANIX — Supplemental Application (Cephalon, LLC)
FDA approved a supplemental application for GRANIX (TBO-FILGRASTIM) submitted by Cephalon, LLC. The approval updates GRANIX's regulatory sta…
-
CLINICAL_TRIALS trial_result · 2017-06-08Clinical Trial Update: Three Immunosuppressive Treatment Regimens for Severe Aplastic Anemia [Phase 2]
Phase 2 trial comparing three immunosuppressive regimens for severe aplastic anemia; results of the study have been posted.
-
CLINICAL_TRIALS trial_result · 2017-03-10Clinical Trial Update: Prophylaxis Trial of Posaconazole Versus Standard Azole Therapy for Neutropenic Patients (Study P01899) [Phase 3]
This Phase 3 trial comparing posaconazole prophylaxis against standard azole therapy in neutropenic patients has completed. It includes pati…
-
CLINICAL_TRIALS trial_result · 2017-03-03Clinical Trial Update: Dose Finding Study of KRN125 (Pegfilgrastim) for Treatment of Neutropenic Patients [Phase 2]
This clinical trial update notes the completion of a Phase 2 dose-finding study of KRN125 (pegfilgrastim) for neutropenia.